Dr. Manoj Unchwal, Dr Aashish Kumar Singh, Dr Nalin Joshi


BACKGROUND: COPD is a chronic inflammatory disease of lung with high mortality and morbidity rate. Complete
blood count parameters provide inflammatory markers, namely neutrophil to lymphocyte ratio (NLR) and platelet to
lymphocyte ratio (PLR). Objective of the study was to compare NLR & PLR in stable COPD and AECOPD.
METHODS: This study was carried out on COPD patients attending Department of Respiratory Medicine during july
2018 to june 2019. 35 stable COPD patients and 35 acute exacerbation cases were enrolled. Routine blood investigation,
NLR and PLR were assessed.
RESULTS: Both NLR (6.389±3.071) and PLR (221.6±92.52) were significantly higher in AECOPD group compared to
stable COPD group.
CONCLUSION: Both NLR and PLR are simple parameters that could be used as cost-effective marker of inflammation in



Full Text:



Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis,management, and prevention of COPD: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176:532-55.

Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 182: 598-604, 2010.

Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. Copd. 2012; 9(2):131±41. Epub 2012/03/ 14. https://doi.org/10.3109/15412555.2011.650239 PMID: 22409371.

Leivseth L, Brumpton BM, Nilsen TI, Mai XM, Johnsen R, Langhammer A. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013; 68: 914-21.

Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann InternMed. 1987; 106: 196-204.

Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor- alpha levels and weight loss in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 1994; 150(5 Pt 1):1453-5.

Trupin L, Earnest G, San Pedro M et al. The occupational burden of chronic obstructive pulmonary disease. European Respiratory Journal 2003; 22(3):462-9.

Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186:982–988.

Han YC, Yang TH, Kim DI, Jin HY, Chung SR, Seo JS, et al. Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Korean Circ J. 2013; 43:93–99.

Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015–1026.

Gronberg AM, Slinde F, Engstrom CP, Hulthen L, Larsson S. Dietary problems in patients with severe chronic obstructive pulmonary disease. Journal of Human Nutrition & Dietetics 2005; 18(6):445-52.

Pena VS, Miravitlles M, Gabriel R et al. Geographic variations in prevalence and under diagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118(4):981-9.

Nathan C. Points of control in inflammation. Nature 2002; 420: 846– 852


  • There are currently no refbacks.